However, the superior in vivo antitumor response of transferred stem-like CD8+ T cells in human cancer (76), as well as the enhanced anti-HIV potential exhibited by reprogrammed CD8+ T cells ex vivo, support the rationale for exploring this immunotherapy, in combination with other methodologies (such as γ-chain cytokines or chimeric antigen receptor cells), in the context of HIV-1 infection. This evidence concerns the gene CD8A and HIV-1 infection.